Efficacy assessments included TWSTRS total ( primary end point ) and subscale scores at weeks 0 , 4 , 8 , 12 ; a pain visual analogue scale at weeks 0 and 4 ; and HRQOL assessed by the SF-36 Health Survey ( SF-36 ; secondary end point ) at weeks 0 and 8 .